Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01294410 · ClinicalTrials.gov registry record · Phase 2
Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 305
- Enrollment target
NCT01294410 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 305 participants.
The verdict
NCT01294410, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 305 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether BMS-936557 is effective in the treatment of moderate to severely active ulcerative colitis in patients who have had insufficient response and/or intolerance to other medical therapy for ulcerative colitis
Interventions
- DRUG Placebo
- DRUG Anti-IP-10 Antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 305 participants |
| Start Date | 2011-03 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01294410
The ClinicalTrials.gov registry entry for NCT01294410 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 305 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01294410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01294410 about?
NCT01294410 is a clinical study titled "Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis". The purpose of this study is to determine whether BMS-936557 is effective in the treatment of moderate to severely active ulcerative colitis in patients who have had insufficient response and/or intolerance to other medical therapy for ulcerative colitis
What is the current status of trial NCT01294410?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 305 participants. The study started on 2011-03. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01294410?
The interventions under investigation include: Placebo (DRUG), Anti-IP-10 Antibody (DRUG).
Who is sponsoring clinical trial NCT01294410?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.